NCT04561570 (REVIVE) is a clinical trial of Vivity ACRYSOF IQ IOL Group in Cataract, sponsored by John Berdahl, MD.

Who is sponsoring NCT04561570?

NCT04561570 is sponsored by John Berdahl, MD.

What drugs are being tested in NCT04561570?

Interventions in NCT04561570: Vivity ACRYSOF IQ IOL Group, ACRYSOF IQ IOL Control Group.

Is NCT04561570 still recruiting?

NCT04561570 is currently completed. Last updated 1 August 2023.

Last reviewed 2023-08-01 · How we verify

NCT04561570: REVIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control

Completed Last updated 1 August 2023

What this trial tests

trial testing Vivity ACRYSOF IQ IOL Group in Cataract in 32 participants. Completed in 27 April 2021.

Timeline

17 September 2020

Primary endpoint
27 April 2021

27 April 2021

Quick facts

Lead sponsor	John Berdahl, MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	32
Start date	17 September 2020
Primary completion	27 April 2021
Estimated completion	27 April 2021
Sites	1 location across United States

Drugs / interventions tested

Vivity ACRYSOF IQ IOL Group
ACRYSOF IQ IOL Control Group

Conditions studied

Cataract — all drugs for Cataract →

Sponsor

John Berdahl, MD

Who can join

Eligibility, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the long-term (\>1 yr) outcomes of the Vivity IOL. The investigator will use similar measurements and procedures to the ones performed on these subjects during the FDA clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04561570 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by John Berdahl, MD
Last refreshed: 1 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04561570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing